CUMYL-NBMINACA|  | 
|
|   [1-(bicyclo[2.2.1]heptan-2-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
 | 
| CAS Number |  | 
|---|
| PubChem CID |  | 
|---|
| ChemSpider |  | 
|---|
| CompTox Dashboard (EPA) |  | 
|---|
|
| Formula | C25H29N3O | 
|---|
| Molar mass | 387.527 g·mol−1 | 
|---|
| 3D model (JSmol) |  | 
|---|
|   CC(C)(C1=CC=CC=C1)NC(=O)C2=NN(C3=CC=CC=C32)CC4CC5CCC4C5
 | 
|   InChI=1S/C25H29N3O/c1-25(2,20-8-4-3-5-9-20)26-24(29)23-21-10-6-7-11-22(21)28(27-23)16-19-15-17-12-13-18(19)14-17/h3-11,17-19H,12-16H2,1-2H3,(H,26,29)Key:MLRLLZWQYJJPEX-UHFFFAOYSA-N
 | 
 CUMYL-NBMINACA (SGT-152, Cumyl-BC[2.2.1]HpMINACA) is a synthetic cannabinoid compound first reported in a 2013 patent,[1] but not identified as a designer drug until 2021, being identified by a forensic laboratory in Germany in February 2021.[2][3] 
 See also
  References
   - ^ WO 2014167530, Bowden MJ, Williamson PB, "Cannabinoid compounds", issued 11 April 2013  
- ^ Pulver B, Riedel J, Schönberger T, Pütz M, Schäper J, Kunert N, et al. (December 2021). "Comprehensive structural characterisation of the newly emerged synthetic cannabimimetics Cumyl-BC [2.2. 1] HpMeGaClone, Cumyl-BC [2.2. 1] HpMINACA, and Cumyl-BC [2.2. 1] HpMICA featuring a norbornyl methyl side chain". Forensic Chemistry. 26: 100371. doi:10.1016/j.forc.2021.100371. S2CID 243179410. 
- ^ "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System" (PDF). June 2022. 
  |  | 
|---|
| Phytocannabinoids (comparison)
 | | Cannabibutols |  | 
|---|
 | Cannabichromenes |  | 
|---|
 | Cannabicyclols |  | 
|---|
 | Cannabidiols |  | 
|---|
 | Cannabielsoins |  | 
|---|
 | Cannabigerols |  | 
|---|
 | Cannabiphorols |  | 
|---|
 | Cannabinols |  CBN CBNACBN-C1CBN-C2CBN-C4CBNM
CBND CBNP CBVD 
 | 
|---|
 | Cannabitriols |  | 
|---|
 | Cannabivarins |  | 
|---|
 | Delta-3-tetrahydrocannabinols |  | 
|---|
 | Delta-4-tetrahydrocannabinols |  | 
|---|
 | Delta-7-tetrahydrocannabinols |  | 
|---|
 | Delta-8-tetrahydrocannabinols |  | 
|---|
 | Delta-9-tetrahydrocannabinols |  | 
|---|
 | Delta-10-Tetrahydrocannabinols |  | 
|---|
 | Delta-11-Tetrahydrocannabinols |  | 
|---|
 | Miscellaneous cannabinoids |  | 
|---|
 | Active metabolites |  | 
|---|
 | 
|---|
| Endocannabinoids |  | 
|---|
| Synthetic cannabinoid
 receptor
 agonists /
 neocannabinoids
 | | Classical cannabinoids (dibenzopyrans)
 |  | 
|---|
 | Non-classical cannabinoids
 |  | 
|---|
 | Adamantoylindoles |  | 
|---|
 | Benzimidazoles |  | 
|---|
 | Benzoylindoles |  | 
|---|
 | Cyclohexylphenols |  | 
|---|
 | Eicosanoids |  | 
|---|
 | Indazole-3- carboxamides
 |  | 
|---|
 | Indole-3-carboxamides |  | 
|---|
 | Indole-3-carboxylates |  | 
|---|
 | Naphthoylindazoles |  | 
|---|
 | Naphthoylindoles |  | 
|---|
 | Naphthoylpyrroles |  | 
|---|
 | Naphthylmethylindenes |  | 
|---|
 | Naphthylmethylindoles |  | 
|---|
 | Phenylacetylindoles |  | 
|---|
 | Pyrazolecarboxamides |  | 
|---|
 | Tetramethylcyclo- propanoylindazoles
 |  | 
|---|
 | Tetramethylcyclo- propanoylindoles
 |  | 
|---|
 | Others |  | 
|---|
 | 
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands |  | 
|---|
| Endocannabinoid enhancers
 (inactivation inhibitors)
 |  | 
|---|
| Anticannabinoids (antagonists/inverse
 agonists/antibodies)
 |  | 
|---|
|  |